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Introduction {#sec001}
============

The mitogen-activated protein kinase (MAPK) cascades are central signaling pathways that regulate a wide range of cellular processes in plant growth, development and stress responses \[[@pgen.1008706.ref001]--[@pgen.1008706.ref003]\]. They function downstream of the cell-surface receptors to deliver and amplify extracellular stimuli that trigger a myriad of cytoplasmic and nuclear responses \[[@pgen.1008706.ref004]\]. Stomatal development and patterning in the model plant Arabidopsis are tightly regulated by a canonical MAPK signaling cascade composed of the MAPKK kinase YODA (YDA), MAPK Kinase 4 and 5 (MKK4/5) and MAPK 3 and 6 (MPK3/6) \[[@pgen.1008706.ref005]--[@pgen.1008706.ref007]\]. Mutants and genetic analyses established a pivotal role of this YDA MAPK signaling pathway in suppressing Arabidopsis stomatal production at early developmental stages \[[@pgen.1008706.ref005]--[@pgen.1008706.ref007]\]. On the other hand, at later developmental stages, a positive regulation on stomatal proliferation was identified that seemed to be achieved by a differently assembled MAPK module of YDA-MKK7/9-MPK3/6 and other unknown MAPKs \[[@pgen.1008706.ref007], [@pgen.1008706.ref008]\].

The MAPK cascades control a diverse variety of biological processes that are achieved by the regulation of a plethora of substrates. In stomatal development, several key factors are modified and regulated by MAPKs. The stomatal lineage initiation is controlled by the bHLH transcription factors SPEECHLESS (SPCH) \[[@pgen.1008706.ref009], [@pgen.1008706.ref010]\] and its partners SCREAM/ICE1 (SCRM/ICE1) and SCRM2 \[[@pgen.1008706.ref011]\]. MPK3/6 phosphorylate SPCH for protein degradation, thus providing a mechanistic link to the suppression of stomatal production \[[@pgen.1008706.ref012]\]. SCRM/ICE1 is also phosphorylated by MPK3/6, so that SCRM/ICE1 protein stability was reduced in cold tolerance \[[@pgen.1008706.ref013]\]. Additionally, recent studies showed that SCRM/ICE1 physically bridges MAPKs and SPCH to initiate the stomata lineage \[[@pgen.1008706.ref014]\].

Besides these strong negative regulation of MPK3/6 signaling in the early stages of stomatal development \[[@pgen.1008706.ref006], [@pgen.1008706.ref012]\], a positive role of the YDA-MKK7/9-MPK3/6 at the late stages was also suggested by the stage-specific manipulation of different tiers of this MAPK cascade in Arabidopsis \[[@pgen.1008706.ref007], [@pgen.1008706.ref008]\]. However, what substrate/s control this cell fate flip remains unknown. Previously, a few collections of putative MAPK substrate proteins were predicted by peptide library screening combined with bioinformatics analysis \[[@pgen.1008706.ref015]\], protein-protein interaction based on yeast two-hybrid screening \[[@pgen.1008706.ref016], [@pgen.1008706.ref017]\], and *in vivo* phosphoproteomic studies \[[@pgen.1008706.ref018]\]. However, detailed functional characterization of these proteins requires significant endeavor, thus the predicted candidates have been seldom further pursued.

The YDA-MKK4/5-MPK3/6 MAPK signaling pathway functions downstream of the plasma membrane receptor-like proteins (RLPs) and kinases (RLKs), including TOO MANY MOUTHS (TMM), the ERECTA family and the Somatic Embryogenesis Receptor Kinase (SERK) family \[[@pgen.1008706.ref019]--[@pgen.1008706.ref023]\]. Upstream of the MAPKKK YDA, a few regulators have been characterized for their functions in plant development, including the SHORT SUSPENSOR (SSP) receptor-associated kinase \[[@pgen.1008706.ref024]\] and the G protein subunit Gβ in zygotic development \[[@pgen.1008706.ref025]\], the GSK3-like BRASSINOSTEROID INSENSITIVE 2 (BIN2) kinase \[[@pgen.1008706.ref026], [@pgen.1008706.ref027]\] and a MAPK scaffold polarity protein BREAKING OF ASYMMETRY IN THE STOMATAL LINEAGE (BASL) in stomatal asymmetric cell division \[[@pgen.1008706.ref028]\]. Their modulation of YDA's function can be achieved by enzymatic inhibition/activation, physical scaffolding for signal specificity and spatiotemporal restriction, *etc*.

Previously, Sörensson *et al*. \[[@pgen.1008706.ref015]\] determined consensus phosphorylation sequences for MPK3/6 in Arabidopsis. They found one of the substrates At1g80180 was phosphorylated by MAPKs and overexpression of it induced stomatal overproduction and clustering \[[@pgen.1008706.ref015]\]. Here, we performed in-depth functional genetics to characterize the three MAPK SUBSTRATES IN THE STOMATAL LINEAGE (MASS) proteins that At1g80180 belongs to for their biological functions in Arabidopsis stomatal development. We found that the MASS proteins are associated with the plasma membrane where they promote the stomatal formation and regulate stomatal patterning. We provide experimental evidence supporting that MAPKs can phosphorylate the MASS proteins *in vitro* and the putative substrates sites may regulate the MASS subcellular localization and protein function, and in turn the MASS proteins interact with YDA at the plasma membrane, possibly suppressing YDA function. Thus, the functional connection between the MASS family and the YDA MAPK cascade provides a new angle to study how external signals through MAPKs fine-tune stomatal development at the plasma membrane.

Results {#sec002}
=======

MASS proteins positively regulate stomata formation {#sec003}
---------------------------------------------------

The previous work by Sörensson et al. showed that At1g80180 is a substrate of MPK3 and MPK6 and overexpression of a phosphor-mimicking version of the protein seemed to generate stomatal overproduction and clustering \[[@pgen.1008706.ref015]\]. Inspired by that, we investigated its biological function in stomatal development and possible functional interaction with the core YDA MPK3/6 pathway in Arabidopsis. At1g80180 encodes a short protein (15 kD) with unknown functions and belongs to a small family of three in the Arabidopsis genome (At1g15400 and At5g20100) ([Fig 1A](#pgen.1008706.g001){ref-type="fig"}). We overexpressed the three genes either in the stomatal lineage cells by using a cell type-specific *BASL* promoter or ubiquitously by using the CaMV *35S* promoter. The results showed that all the transgenic populations produced similar stomatal phenotypes: overproliferated stomatal guard cells in a clustered pattern ([Fig 1B--1D](#pgen.1008706.g001){ref-type="fig"} and [S1A Fig](#pgen.1008706.s001){ref-type="supplementary-material"}). The elevated transcript levels in these overexpression lines were demonstrated by real-time PCR ([Fig 1E](#pgen.1008706.g001){ref-type="fig"}). The phenotypes suggest that all three genes might promote stomatal production and regulate stomatal patterning, therefore they are named as *MAPK SUBSTRATES IN THE STOMATAL LINEAGE* (*MASS*) *1*, *2*, and *3* ([Fig 1A](#pgen.1008706.g001){ref-type="fig"}).

![Stomatal phenotypes caused by MASS overexpression.\
(A) Phylogenetic tree of the Arabidopsis MASS family. (B) Stomatal phenotypes induced by MASS1/2/3. Confocal images of 3-dpg adaxial side of cotyledon epidermis in WT (Col) and overexpression seedlings of GFP-MASS1, GFP-MASS2g, and GFP-MASS3, all driven by the *BASL* promoter. Cell outlines were stained with propidium iodide (PI, magenta). Brackets indicate stomatal clusters. Scale bar represents 50 μm. (C) Quantification of the numbers of stomatal clusters per cotyledon in 10-dpg seedlings of the designated plants. (D) Quantification of stomatal index (SI) in 5-dpg adaxial cotyledons of the designated seedlings. (E) Quantitative real-time PCR analysis of *MASS1/2/3* expressions in WT and GFP-MASS transgenic lines in (B). \*significantly different compared with the WT (Col) values (Student's *t*-test, \*P \< 0.05, \*\*P \< 0.01).](pgen.1008706.g001){#pgen.1008706.g001}

To functionally characterize the three *MASS* genes, we analyzed their promoter activity by examination of the transcriptional reporter lines that drive the expression of nuclear YFP (nucYFP) in plants. We found that all three promoters were broadly active in the leaf epidermal cells albeit with preferred cell type-specificity ([S1B Fig](#pgen.1008706.s001){ref-type="supplementary-material"}) and in some other tissues, e.g. the hypocotyl and root, at the seedling stage ([S1B Fig](#pgen.1008706.s001){ref-type="supplementary-material"}). We collected single T-DNA insertional mutants and crossed them to generate double and triple mutants ([Fig 2A](#pgen.1008706.g002){ref-type="fig"} and [S2A Fig](#pgen.1008706.s002){ref-type="supplementary-material"}). The transcript levels of the three genes in the triple *mass1;2;3* mutants were assessed by real-time PCR ([Fig 2E](#pgen.1008706.g002){ref-type="fig"}) and the data show that, while *mass3* is a knock-down, *mass1* and *mass2* are null mutations. Quantification of stomatal production in 5-day old cotyledons suggested that the triple mutant produced lowered stomatal index ([Fig 2A and 2F](#pgen.1008706.g002){ref-type="fig"}), consistent with the overexpression data ([Fig 1B--1D](#pgen.1008706.g001){ref-type="fig"} and [S1A Fig](#pgen.1008706.s001){ref-type="supplementary-material"}), supporting a positive role of the *MASS* genes in stomatal production. We also characterized the lower-order mutants (singles and doubles) and found that the double mutant *mass 1;3*, but not *mass1*;2 and *mass2*;3, produced reduced numbers of stomata, though to a less extent when compared with those of the triple mutants ([Fig 2F](#pgen.1008706.g002){ref-type="fig"}). None of the three single mutants showed any discernable defects in general growth and stomatal development. Thus, our mutant analyses indicated a redundantly positive role of the three *MASS* genes in stomatal production.

![MASS positively regulates stomata formation.\
(A) Confocal images of 3-dpg adaxial side of the cotyledon epidermis in WT (Col) and *mass1;2;3* mutant seedlings. (B) DIC images of 5-dpg cotyledons in WT and *mass1;2;3-crispr \#5* seedlings. (C) Confocal images of 3-dpg adaxial side of the cotyledon epidermis in complementation lines *MASS1p*::YFP-MASS1 and *MASS2p*::YFP-MASS2g in *mass1;2;3* background. (D) DIC images of 5-dpg cotyledons in *mass1;2;3-crispr* \#7 and complementation seedlings expressing the crispr-resistant version of MASS2g (rMASS2g). Cell outlines in (A-D) were stained with PI (magenta). Guard cells in (B, D) were highlighted in pink for better visualization. Scale bars represent 50 μm in (A-D). (E) Quantitative real-time PCR analysis of *MASS1/2/3* expressions in WT and *mass1;2;3* mutant. (F) Quantification of SI in 5-dpg adaxial cotyledons of T-DNA mutants. (G) Quantification of SI in 5-dpg adaxial cotyledons of *mass1;2;3-crispr \#7* mutant and the designated complementation lines. \*significantly different compared with the WT (Col) values (Student's *t*-test, \*P \< 0.05, \*\*P \< 0.01). n.s: not significant.](pgen.1008706.g002){#pgen.1008706.g002}

To consolidate the loss-of-function phenotypes, we deployed the CRISPR/Cas9-mediated genome-editing strategy \[[@pgen.1008706.ref029]\] to create genetic lesions in all three *MASS* genes (sgRNA positions shown in [S2A Fig](#pgen.1008706.s002){ref-type="supplementary-material"}). The wild-type plants Columbia-0 (Col) plants were transformed with the CRISPR/Cas9 construct that carried three sgRNAs, each of which should specifically target one of the three *MASS* genes. Two independent triple mutant lines (T3) were established (*mass1;2;3-crispr\#5* and *\#7*, see the mutated sequences and genotyping data in [S2B and S2C Fig](#pgen.1008706.s002){ref-type="supplementary-material"}), in which three genes were either early terminated in translation or made internal deletions ([S2C Fig](#pgen.1008706.s002){ref-type="supplementary-material"}). Phenotypic characterization of stomatal development suggested that the CRISPR-generated mutants were similar to the T-DNA mutagenized triple mutants ([Fig 2B and 2D](#pgen.1008706.g002){ref-type="fig"}, and [S2D Fig](#pgen.1008706.s002){ref-type="supplementary-material"}), in both of which stomatal indices were lowered to around 20% compared to that of the wild-type (23%, n = 14 individual plants) ([Fig 2F and 2G](#pgen.1008706.g002){ref-type="fig"}).

With respective to genetic complementation, we introduced the expression of N-terminal YFP fused MASS1 and MASS2, both driven by their endogenous promoters, into the T-DNA *mass1*;2;3 mutants ([Fig 2C](#pgen.1008706.g002){ref-type="fig"}, [S3A and S3B Fig](#pgen.1008706.s003){ref-type="supplementary-material"}). We also introduced a CRISPR/Cas9-resistant version of mCherry-rMASS2 (rMASS2 containing nucleotide mutations in the sgRNA targeting site without changing the MASS2 amino acid sequence) into *mass1;2;3-crispr\#7* plants ([Fig 2D](#pgen.1008706.g002){ref-type="fig"}). In both cases, we found that the mutant phenotypes were recovered by YFP-MASS1/2 ([Fig 2C and 2D](#pgen.1008706.g002){ref-type="fig"}) and the lowered stomatal indices in the *crispr* mutants were recovered by expression of mCherry-rMASS2 back to the wild-type levels ([Fig 2G](#pgen.1008706.g002){ref-type="fig"}). Again, both MASS1 and MASS2 protein expressions were detected in the leaf tissues, with more abundant expression of *MASS2* in the epidermis and *MASS1* in the mesophyll layer ([S3A and S3B Fig](#pgen.1008706.s003){ref-type="supplementary-material"}). The subcellular distribution patterns of MASS1 and MASS2 ([S3A and S3B Fig](#pgen.1008706.s003){ref-type="supplementary-material"}) in *Arabidopsis* were comparable with those in tobacco epidermal cells ([Fig 3A and 3B](#pgen.1008706.g003){ref-type="fig"}); both were localized to the nucleus and the plasma membrane (see below for more details). In parallel, we also generated C-terminal tagged MASS proteins for complementation. Because the orientation of such fusions may disturb the C-terminal motif that is critical for MASS function (see below about MASS2 subdomains), they were therefore abandoned for further analysis. Thus, collectively, our genetic evidence (loss-of-function and overexpression) suggested that the three MASS genes may redundantly contribute to promoting stomatal production in Arabidopsis.

MASS functions at the plasma membrane {#sec004}
-------------------------------------

By amino acid sequence analysis, no functionally annotated domains can be recognized in the three MASS proteins. To characterize the biological functions of these novel regulators, we analyzed their protein subcellular localization by examining the N-terminal fluorescent protein-tagged MASS proteins in both tobacco epidermal cells and Arabidopsis stomatal lineage cells ([Fig 3A--3F](#pgen.1008706.g003){ref-type="fig"}). The genomic regions of *MASS1* and *MASS3* do not contain introns, thus their genomic/coding sequences were amplified for constructing the reporter lines (CFP/YFP-MASS1/3). As three alternative splicing sites were annotated for *MASS2* ([S2A Fig](#pgen.1008706.s002){ref-type="supplementary-material"}), we amplified the genomic region flanking all three variants to generate the reporter line (CFP/YFP-MASS2g). The localization data in tobacco cells showed that the three MASS proteins were differentially distributed at the subcellular level: MASS1 and MASS2 appeared in the nucleus and at the plasma membrane, whilst MASS3 predominantly localized at the plasma membrane ([Fig 3A--3C](#pgen.1008706.g003){ref-type="fig"}). When the three genes were expressed in the stomatal lineage cells (driven by the *BASL* promoter), they showed consistently differential expression patterns as in tobacco epidermal cells, with MASS1 and MASS2 dually localized in the nucleus and at the plasma membrane, while MASS3 mainly at the plasma membrane ([Fig 3D--3F](#pgen.1008706.g003){ref-type="fig"}).

![MASS functions at the plasma membrane.\
(A-C) Protein subcellular localization (cyan) in tobacco epidermal cells leaves. Confocal images of tobacco epidermis transiently expressing CFP-MASS1 (A), CFP-MASS2g (B), and CFP-MASS3 (C), all of which were driven by the *35S* promoter. Scale bars represent 50 μm. (D-F) Protein localization (green) in the stomatal lineage cells in Arabidopsis. Confocal images of 3-dpg adaxial cotyledon epidermis expressing YFP-MASS1 (D), YFP-MASS2g (E), and YFP-MASS3 (F), all driven by the *BASL* promoter. Scale bars represent 10 μm. (G-I) Stomatal phenotypes triggered by expressing MASS2 and other variants. Confocal images of 3-dpg adaxial cotyledon epidermis expressing GFP-MASS2g (G), myr-GFP-MASS2g (H), and YFP-NLS-MASS2g (I). Green shows GFP-MASS expression pattern. Scale bars represent 50 μm. Brackets indicate stomatal clusters and abnormal cell divisions. (J) Index of clustered stomata in 5-dpg adaxial cotyledons of designated plants. Cell outlines in (G-I) were stained with PI (magenta). \*significantly different compared the WT (Col) (Student's *t*-test, \*P \< 0.05, \*\*P \< 0.01).](pgen.1008706.g003){#pgen.1008706.g003}

Because the MASS2 protein showed expression at both subcellular locations and overexpression of it generated elevated number and clustered stomatal lineage cells ([Fig 3B, 3E and 3G](#pgen.1008706.g003){ref-type="fig"}), we tested where its biological location is, in the nucleus, or at the plasma membrane, or both. As in the MASS protein sequences, no signal peptides for apoplast secretion or transmembrane domains to span the membranes were predicted, we added a myristoylation lipid modification site \[[@pgen.1008706.ref030]\] to artificially tether MASS2 to the plasma membrane. Indeed, myr-GFP-MASS2g was found exclusively at the plasma membrane and, interestingly, overexpression of this membrane-attached version recapitulated, and even slightly enhanced, the stomatal clustering phenotypes caused by the overexpression of the wild-type protein ([Fig 3H and 3J](#pgen.1008706.g003){ref-type="fig"}). On the other hand, when fused with a nuclear localization signal (NLS), YFP-NLS-MASS2g showed the anticipated nuclear-only pattern, but this version did not induce any obvious stomatal phenotypes ([Fig 3I and 3J](#pgen.1008706.g003){ref-type="fig"}). The same strategies were applied to the dually localized MASS1 protein as well, and the data consistently show that plasma membrane-only but not nuclear-localized MASS1 promoted stomatal production ([S3C and S3D Fig](#pgen.1008706.s003){ref-type="supplementary-material"}). Thus, collectively, our data suggested that the positive regulation of the MASS proteins in stomatal development arises from the plasma membrane pool, but not from the nuclear pool.

Fine-scale analysis of the MASS2 subdomains {#sec005}
-------------------------------------------

As the MASS2 proteins do not contain transmembrane domains, its association with the plasma membrane might be achieved by protein-protein or protein-lipid interactions in plant cells. Considering MASS2 has three splicing variants ([S4A Fig](#pgen.1008706.s004){ref-type="supplementary-material"}), we first examined their subcellular localization (N-terminal GFP fusions driven by the *BASL* promoter) and found that all of them showed the typical dual localization with slight differences in the preferential partition ([S4B Fig](#pgen.1008706.s004){ref-type="supplementary-material"}). MASS2.3, as the longest one ([S4A Fig](#pgen.1008706.s004){ref-type="supplementary-material"}), was used as a representing member to align with MASS1 and 3 for subdomain analysis ([S4C Fig](#pgen.1008706.s004){ref-type="supplementary-material"}). The three MASS proteins show high similarity at the two terminal regions but are not conserved in the middle ([Fig 4A](#pgen.1008706.g004){ref-type="fig"} and [S4C Fig](#pgen.1008706.s004){ref-type="supplementary-material"}). We thus split MASS2.3 into two halves to make GFP-tagged MASS2.3_N76 and MASS2.3_C72, both driven by the *BASL* promoter ([Fig 4A](#pgen.1008706.g004){ref-type="fig"}). The results showed that both truncations failed to localize correctly. The first half GFP-MASS2.3_N76 lost the distinct localization in the nucleus, whereas the second half GFP-MASS2.3_C72 lost the plasma membrane localization ([Fig 4B--4D](#pgen.1008706.g004){ref-type="fig"}). To further narrow down the critical segments for specific localization at the plasma membrane and in the nucleus, respectively, we deleted the highly conserved regions at the two ends to create GFP-MASS2.3_Δ29N (the N-terminal 29 amino acids deleted), GFP-MASS2_Δ13C and GFP-MASS2_Δ25C (the C-terminal 13 and 25 amino acids deleted, respectively) ([Fig 4A](#pgen.1008706.g004){ref-type="fig"}). The subcellular localization data clearly demonstrated that GFP-MASS2.3_Δ29N was only shown in the nucleus, suggesting the N-terminal 29-aa is required for the plasma membrane-association, while GFP-MASS2_Δ13C was only found at the plasma membrane, supporting that the C-terminal 13-aa determines the nuclear accumulation ([Fig 4E--4G](#pgen.1008706.g004){ref-type="fig"}). Interestingly, the plasma membrane-only GFP-MASS2_Δ13C promoted stomata production and clustering, a phenotype resembling that of the full-length MASS2 overexpression ([Fig 4H and 4I](#pgen.1008706.g004){ref-type="fig"}), again supporting the biological function of MASS2 at the plasma membrane. However, the further shortened MASS2.3_Δ25C, albeit successfully localized to the plasma membrane, failed to induce stomatal overproduction ([Fig 4J](#pgen.1008706.g004){ref-type="fig"}), hinting the critical role of the small region between Δ13C and Δ25C for its biological function in stomatal development (marked in [Fig 4A](#pgen.1008706.g004){ref-type="fig"}). In addition, none of the other shortened versions, MASS2.3_N76, MASS2.3_C72 and MASS2.3_Δ29N, were sufficient to trigger this phenotype ([S4D Fig](#pgen.1008706.s004){ref-type="supplementary-material"}), probably due to the lack of either plasma membrane association or the critical functional region. Taken together, we established that the MASS proteins promote stomatal formation at the plasma membrane and we defined three specific regions in MASS2.3 that are important for nuclear accumulation, plasma membrane association, and the biological function at the plasma membrane, respectively ([Fig 4A](#pgen.1008706.g004){ref-type="fig"}).

![Fine-scale analysis of the MASS2 subdomains.\
(A) Diagram of MASS2.3 subdomains with proposed functions. N76, the N-terminal domain containing 76-aa; C72, the C-terminal domain containing 72-aa; Δ29N, the N-terminal 29-aa deleted; Δ13C, the C-terminal 13-aa delete; Δ25C, the C-terminal 25-aa deleted. (B-G) Confocal images of 3-dpg adaxial cotyledon epidermis showing the localization of GFP-fused MASS2.3 variants (green). (H-J) Confocal images of 3-dpg adaxial cotyledon epidermis showing stomatal phenotypes of expressing GFP-MASS2.3 full-length and truncated versions (green). Brackets indicate stomatal clusters and abnormal cell divisions. Cell outlines in (H-J) were stained with PI. Scale bar represents 20 μm in (B-G) and 50 μm in (H-J).](pgen.1008706.g004){#pgen.1008706.g004}

MPK6-mediated phosphorylation and possible connection with MASS localization and function {#sec006}
-----------------------------------------------------------------------------------------

Sörensson et al. (2012) previously demonstrated that MASS1 is phosphorylated by MPK6 *in vitro* kinase assays \[[@pgen.1008706.ref015]\]. We further tested MASS2 recombinant proteins. Because one of the splicing variants, MASS2.2, is most similar to MASS1, we purified the MASS2.2 recombinant proteins and found that MASS2.2 was phosphorylated by *in vitro* constitutively active MKK5 (MKK5^DD^)-activated MPK6 ([Fig 5A](#pgen.1008706.g005){ref-type="fig"}). In parallel, mutating the serine residue (S107) to alanine (A) in the conserved MAPK-substrate P-P-[S]{.ul}-P motif abolished the MPK6-mediated phosphorylation of MASS2.2 ([Fig 5A](#pgen.1008706.g005){ref-type="fig"}), supporting that MASS2 is phosphorylated by MPK6 at the S107 site *in vitro*, consistent with the previous study that MASS2 was found phosphorylated among isolated plasma membrane-enriched phospho-peptides in Arabidopsis \[[@pgen.1008706.ref031]\].

![MPK6-mediated phosphorylation regulates MASS localization and function.\
(A) *In vitro* kinase assay showing MKK5^DD^-activated MPK6 phosphorylation of MASS2.2. (B) Upper panel showing the localization of YFP-tagged MASS1 and MASS1 phosphor-variants (green). Lower panel shows the YFP intensity profiling along the lines drawn in the above images. Red arrows indicate YFP signals at the plasma membrane. Scale bars represent 10 μm. (C) Quantification of YFP intensity partition in designated subcellular regions shown in (B). (D) Upper panel, confocal images showing localization of YFP-tagged MASS2.2 and phosphor-variants. Lower panel, intensity profiling of the corresponding YFP signals along the lines drawn in the above images. Red arrows indicate YFP signals at the plasma membrane. Scale bars represent 10 μm. (E, F) Quantification of clustered stomata index in 5-dpg adaxial cotyledons expressing YFP-tagged MASS2.2 and phosphor-variants (E) and myristoylated GFP-tagged proteins as designated (F). \* in (E), significantly different compared with the WT (Col) values. \*\* in (F) significantly different between the two samples being compared (bars). (Student's *t*-test, \*P \< 0.05, \*\*P \< 0.01). n.s: not significant.](pgen.1008706.g005){#pgen.1008706.g005}

Phosphorylation may alter protein subcellular localization. We manipulated the phosphorylation site of MASS1 (S105) by generating a phospho-deficient version MASS1^S105A^ and a phospho-mimicking version MASS1^S105D^, respectively. By examining the YFP-tagged proteins, we found that phosphorylation status is influential to MASS1 subcellular distribution because neither MASS1^S105A^ nor MASS1^S105D^ showed robust plasma membrane-association, but both more abundantly accumulated in the nucleus ([Fig 5B and 5C](#pgen.1008706.g005){ref-type="fig"} and [S5A Fig](#pgen.1008706.s005){ref-type="supplementary-material"}). With respective to the MASS2 localization, because we established that MASS2.2 was phosphorylated by MPK6 *in vitro* ([Fig 5A](#pgen.1008706.g005){ref-type="fig"}), we assessed the localization pattern of YFP-MASS2.2^S107A^ and YFP-MASS2.2^S107D^ in the stomatal lineage cells. Consistently, the fluorescence intensity profiling results demonstrated that both versions showed reduced abundance at the plasma membrane but elevated accumulation in the nucleus ([Fig 5D](#pgen.1008706.g005){ref-type="fig"} and [S5B Fig](#pgen.1008706.s005){ref-type="supplementary-material"}). However, we did not detect an obvious change of the PM localization of MASS1 and MASS2 when MPK3/6 signaling was disturbed by overexpression of the dominant-negative *MPK6AEF* or chemically inhibiting MPK6 in *mpk3*;6 null mutants \[[@pgen.1008706.ref032]\]([S6A--S6C Fig](#pgen.1008706.s006){ref-type="supplementary-material"}). It is possible that some MPK3/6 activity leakage was sufficient to maintain MASS localization or other kinases may mediate MASS phosphorylation. Taken together, the combined data of *in vitro* phosphorylation and *in vivo* protein localization suggested that MAPK-mediated phosphorylation may contribute to the MASS proteins to localize robustly at the plasma membrane, though it is still possible that the manipulation of the phosphorylation sites may alter protein conformation thus protein-protein interaction for localization and function. The failure of D versions (YFP-MASS1^S105D^ and YFP-MASS2.2^S107D^) to localize robustly at the plasma membrane was not anticipated but suggested that dephosphorylation might be equally important for these proteins to correctly localize.

To further assess the impact of protein phosphorylation on their biological functions, we first overexpressed YFP-MASS2.2, MASS2.2^S107A^, and MASS2.2^S107D^ in the stomatal lineage cells by using the *BASL* promoter. Our results show that MASS2.2 did not seem to function as effectively as MASS2g in triggering stomatal clusters and neither of the mislocalized phospho-variants MASS2.2^S107A^ and MASS2.2^S107D^ produced significant stomatal phenotypes ([Fig 5E](#pgen.1008706.g005){ref-type="fig"}). Considering the functional location of MASS at the plasma membrane, we modified MASS2.2 and the other two variants with the myristoylation site. When tethered to the plasma membrane, myr-GFP-MASS2.2 induced stronger stomatal clustering. However, neither myr-GFP-MASS2.2^S107A^ nor myr-GFP-MASS2.2^S107D^ could function at a comparable level in generating stomatal clusters ([Fig 5F](#pgen.1008706.g005){ref-type="fig"}). Thus, we suspect that these putative MAPK phosphorylation sites need to stay open for both phosphorylation and dephosphorylation, so that MASS may achieve their function at the plasma membrane in stomatal development. Compared to the previous discoveries by Sörensson et al. that phosphomimick MASS1 trigged more stomatal production, our findings suggested that phosphorylation of MASS2 is critical for protein localization and, more interestingly, the reversible phosphorylation-dephosphorylation might be equally, if not more, important for MASS2 function.

MASS interacts with the MAPKK Kinase YDA {#sec007}
----------------------------------------

The *mass* triple mutants occasionally showed a cotyledon-fusion phenotype ([S6D Fig](#pgen.1008706.s006){ref-type="supplementary-material"}), to a certain extent resembling that of a plant expressing the constitutively active MAPKKK YDA (YDA^CA^) \[[@pgen.1008706.ref005]\]. In addition, similar to the MASS proteins, YDA is also a peripheral membrane protein in plant cells \[[@pgen.1008706.ref028]\]. To test whether the *MASS* genes are functionally connected to YDA, we first examined the physical interaction between MASS2 with YDA. Indeed, positive protein-protein interactions were detected between YDA and MASS2 based on yeast two-hybrid and *in vitro* pull-down assays ([Fig 6A and 6B](#pgen.1008706.g006){ref-type="fig"}). To test their interaction in plant cells, we assayed the kinase-inactive version of YDA (YDA^KI^ with one point mutation K429R, \[[@pgen.1008706.ref007]\]) because overexpression of the catalytically active enzyme often causes cell death in tobacco \[[@pgen.1008706.ref033]\]. In the bimolecular fluorescence complementation (BiFC) assay in tobacco epidermal cells, the recovered split YFP signals supported that all three MASS proteins may physically interact with YDA^KI^ at the plasma membrane ([Fig 6C](#pgen.1008706.g006){ref-type="fig"} and [S7A Fig](#pgen.1008706.s007){ref-type="supplementary-material"}). The interaction between YDA and MASS was further confirmed by co-immunoprecipitation (IP) analysis in tobacco leaf cells and by the biolayer interferometry (BLI) assay *in vitro* ([Fig 6D](#pgen.1008706.g006){ref-type="fig"} and [S7B Fig](#pgen.1008706.s007){ref-type="supplementary-material"}). In Arabidopsis stomatal lineage cells, we co-expressed mCherry-MASS2 and YDA^KI^-YFP (driven by the *SPCH* promoter) and the two proteins co-existed at the plasma membrane. Furthermore, Z-projected confocal images showed that MASS2 forms cortical punctate that overlap with some YDA^KI^-accumulating dots at the plasma membrane ([Fig 7A](#pgen.1008706.g007){ref-type="fig"}), though the properties of which have not been characterized yet. Taken together, our data suggested that the MASS proteins might function through their physical interaction with YDA at the plasma membrane.

![MASS2 interacts with YDA.\
(A) Yeast two-hybrid assay for MASS2.2 interaction with YDA. The BD and AD empty vectors were used as negative controls. Interaction tests were shown on the medium supplemented with -Leu-Trp-His. (B) *In vitro* pull-down assays using recombinant proteins, MBP-YDA and His-MASS2.3. MBP alone was used as negative control. Immunoblots were visualized by anti-His and anti-MBP. (C) BiFC assays to test the interaction between YDA^KI^ and MASS2 in tobacco leaf epidermis. The expression of half YFPs (YFP^N^ and YFP^C^) were used as negative controls. Scale bars represent 50 μm. (D) Co-IP assay to test the interaction between YDA^KI^ and MASS2. 35S::4xMyc-MASS2g was transiently co-expressed with 35S::YDA^KI^-YFP or 35S::YFP in tobacco leaves.](pgen.1008706.g006){#pgen.1008706.g006}

![Working model for MASS function in stomatal development.\
(A) Confocal images showing co-localization of *BASLp*::mCherry-MASS2g with *SPCHp*::YDA^KI^-YFP in Arabidopsis. Bottom panels showing zoomed-in images for protein co-localization. White arrows indicate where co-localizations were found. Scale bars represent 50 μm in the upper panel and 10 μm in the lower panel. (B) DIC images of 5-dpg seedlings showing stomatal phenotypes generated by *35S*::CFP-MASS2g, *SPCHp*::YDA^CA^-YFP, and the crossed line co-expressing both proteins. The MASS2g overexpression releases the suppression of stomatal production induced by YDA^CA^. Scale bars represent 50 μm. (C) A proposed working model for the MASS proteins: Protein phosphorylation and de-phosphorylation are required for MASS to robustly localize at the plasma membrane. MPK3/6-mediate protein phosphorylation may regulate both localization and function of MASS. At the plasma membrane, MASS interacts with the MAPKKK YDA, thereby directly or indirectly interfer with the MAPK signaling in stomatal development. This model does not exclude other regulators functioning with MASS to regulate stomatal development and patterning in Arabidopsis.](pgen.1008706.g007){#pgen.1008706.g007}

Based on the phenotypes shown in the loss-of-function and overexpression plants, we hypothesized that the MASS family might promote stomatal production through suppressing the YDA MPK3/6 signal pathway, possibly via directly interacting with YDA. To test this hypothesis, we overexpressed CFP-MASS2g in plants expressing YDA^CA^-YFP (constitutively active YDA driven by the stomatal lineage-specific *SPCH* promoter). While YDA^CA^ suppresses stomatal differentiation ([Fig 7B](#pgen.1008706.g007){ref-type="fig"} and \[[@pgen.1008706.ref005]\]), interestingly, the introgression of CFP-MASS2 suppressed the YDA^CA^-induced phenotype by restoring the formation of stomatal lineage cells ([Fig 7B](#pgen.1008706.g007){ref-type="fig"}). Biochemically, by using the p42/44 MAPK antibody that detects activated MPK3 and 6 in Arabidopsis, we found that activated levels of MPK3/6 were elevated in the loss-of-function mutants but lowered in the *MASS2* overexpression plants ([S7C Fig](#pgen.1008706.s007){ref-type="supplementary-material"}). However, incubation of the MASS2 protein with YDA^CA^ did not seem to alter YDA kinase activity *in vitro* ([S7D Fig](#pgen.1008706.s007){ref-type="supplementary-material"}). We suspect that either MASS2 has to be properly modified to function *in vivo* or other interacting proteins that interact with MASS to participate in the regulation of YDA MAPK signaling. At the plasma membrane, the receptor-like kinases ER could also possibly interact with MASS. When MASS2 overexpression was introduced into *er* mutants, an additive stomatal phenotype was observed ([S8A Fig](#pgen.1008706.s008){ref-type="supplementary-material"}), suggesting that the MASS function does not seem to rely on the presence of the ER receptor. The plasma membrane-localized polarity protein BASL was also examined in MASS2 overexpression plants but no discernable changes of GFP-BASL localization were noticed ([S8B Fig](#pgen.1008706.s008){ref-type="supplementary-material"}). Collectively, our results supported that the positive role of MASS in stomatal production might be achieved by physical interaction with YDA thus the suppression of the MAPK signaling pathway in Arabidopsis ([Fig 7C](#pgen.1008706.g007){ref-type="fig"}). However, since MASS did not seem to suppress YDA activity directly in our *in vitro* assays ([S7D Fig](#pgen.1008706.s007){ref-type="supplementary-material"}), we propose that MASS may function as a scaffold that recruits other regulators of the MAPK signal pathway.

Discussion {#sec008}
==========

MAPK cascades convert and amplify environmental and developmental cues into adapted intracellular responses. Their functions are particularly important for signal transduction in sessile plants that are incapable of escaping from a stressing environment. With a large number of potential kinase-substrate relationships of plant MAPKs revealed by *in vitro* and *in vivo* strategies \[[@pgen.1008706.ref015], [@pgen.1008706.ref018]\], most putative MAPK substrates remained functionally elusive. Plant MAPKs usually are expressed in the cytosol and/or nucleus, therefore their substrates at different subcellular localizations are thought to largely determine signal specificity and the spatiotemporal dynamics of MAPK signaling in a biological process \[[@pgen.1008706.ref034]\]. In Arabidopsis stomatal development, SPCH and SCRM/ICE1 are nuclear transcription factors targeted by MPK3/6 for protein degradation \[[@pgen.1008706.ref012]--[@pgen.1008706.ref014]\], so that stomatal formation can be modulated by MAPK upstream signals. The polarity protein BASL in the regulation of stomatal asymmetric cell division is phosphorylated by MPK3/6 for its localization at the cell cortex where BASL functions as a MAPK scaffold protein to locally concentrate the YDA MAPK signaling to differentiate daughter cell fates \[[@pgen.1008706.ref028], [@pgen.1008706.ref035]\]. In this study, we established the functions of a newly identified MAPK substrate family, the MASS proteins, in the regulation of stomatal development and patterning in Arabidopsis. Phenotypic analysis of the loss-of-function mutants suggested that MASS functions to promote stomatal production and the overexpression phenotype revealed an additional role of MASS in stomatal patterning ([Fig 1](#pgen.1008706.g001){ref-type="fig"} and [S1 Fig](#pgen.1008706.s001){ref-type="supplementary-material"}).

The dual localization of the MASS proteins {#sec009}
------------------------------------------

The subcellular localization revealed by the fluorescent protein-tagged MASS proteins suggested that MASS1 and MASS2 are dually localized to the nucleus and at the plasma membrane, except for MASS3 that only appeared at the plasma membrane ([Fig 3](#pgen.1008706.g003){ref-type="fig"}). But overexpression of this plasma membrane-only MASS3 induced comparable stomatal phenotypes as those generated by overexpression of MASS1, MASS2, and their myristoylated versions ([Fig 1](#pgen.1008706.g001){ref-type="fig"} and [Fig 3](#pgen.1008706.g003){ref-type="fig"}), consistently suggesting the biological activities of all three MASS proteins occur at the plasma membrane.

Why doesn't MASS3 localize into the nucleus? This probably can be explained by its protein sequence, in particular at the very C-terminal end ([S4C Fig](#pgen.1008706.s004){ref-type="supplementary-material"}). Based on our domain analyses of MASS2.3, the nuclear localization-determining fragment has been narrowed down to the C-terminal last 13 amino acids ([S4C Fig](#pgen.1008706.s004){ref-type="supplementary-material"}) beginning with a 5 amino acid-long, basic residue-rich motif (K-R-R-S-R). This motif is fully conserved in MASS1 and MASS2 but divergent in MASS3 (S-G-G-S-T). Considering that MASS1 and MASS2 both are dually localized and MASS3 is excluded from the nucleus, we suspect that this conserved K/R-rich motif is possibly a nuclear localization signal, which usually mediates the interaction with importins for nucleocytoplasmic transport \[[@pgen.1008706.ref036]\], and that the absence of this motif in MASS3 results in the failure of the protein to localize in the nucleus.

With regards to the plasma membrane localization of MASS proteins, the highly conserved N-terminal regions aligned with the first 29 amino acids of MASS2.3 seemed to be required, though no obvious features, e.g. high hydrophobicity, lipid modification, etc., could be recognized to explain the mechanisms for the plasma membrane localization. In parallel, our work also suggested that MAPK-mediated phosphorylation of the highly conserved serine residue in the P-P-S-P motif ([S4C Fig](#pgen.1008706.s004){ref-type="supplementary-material"}) is required for MASS to localize and function at the plasma membrane. Therefore, we propose that the factor/s determining MASS to localize to the plasma membrane may involve protein-protein and/or protein-lipid iterations with both the N-terminal 29-aa and the conserved P-P-S-P phosphorylation site.

Possible functions of MASS at different subcellular localizations {#sec010}
-----------------------------------------------------------------

Our findings show that, interestingly, the localization pattern and functional fashion of the MASS proteins, to some extent, mimic those of the polarity protein BASL \[[@pgen.1008706.ref037]\]. For example, both are membrane-associated proteins that appear to be dynamically distributed between the nucleus and the plasma membrane ([Fig 3A--3F](#pgen.1008706.g003){ref-type="fig"}) \[[@pgen.1008706.ref035]\]. Although MASS is not polarized, both proteins function at the plasma membrane but not in the nucleus \[[@pgen.1008706.ref037]\]. Also, both proteins are MAPK substrates and phosphorylation is important for their subcellular localization and biological function ([Fig 5](#pgen.1008706.g005){ref-type="fig"}) \[[@pgen.1008706.ref028]\]. In addition, both proteins appear to interact with the MAPKKK YDA at the cell cortical region. Base on the data we collected, we propose that the nuclear pool of MASS proteins, similar to that of BASL, might serve as a storage form that can be quickly targeted by MAPK signaling and redistributed to the target locations, without synthesizing new proteins, to respond to external stimuli. Meanwhile, we should not discount the possibility that MAPKs may phosphorylate MASS proteins that are in the cytoplasm or associated with the PM. Particularly, for MASS3 that is not expressed in the nucleus, the cytoplasm region can be a buffering zone. This possibility can be further tested by the deletion of the N-terminal 29 amino acids and mutating the conserved phosphorylation site.

Our complementation data using the myristoylated versions supported that the MASS proteins promote stomatal production at the plasma membrane. Then, what is the molecular mechanism for MASS to function there? We provided evidence that MASS proteins may interact with the MAPKKK YDA at the cell periphery, where MASS is hypothesized to negatively impact on the MAPK signaling cascade that suppresses the protein abundance of the key stomatal factor SPCH in production and proliferation of the lineage cells \[[@pgen.1008706.ref006], [@pgen.1008706.ref012]\]. However, which form (phosphorylated or dephosphorylated) of MASS may preferentially associate with YDA and how MASS proteins mechanistically suppress YDA functions, directly or indirectly, at the plasma membrane requires more in-depth investigation. There are more questions, for example, what the stability of the MASS proteins is at the plasma membrane and what controls the dynamic nuclear/cytoplasmic partition in the cells, to be addressed for better understanding the potential feedback regulation between MASS and the MAPK signaling pathway (see the model in [Fig 7C](#pgen.1008706.g007){ref-type="fig"}).

Also, we noted that one major phenotype caused by MASS overexpression was clustered stomata, a phenotype reflecting defective cell-cell communication. In most dicot leaves, stomata are spaced out by at least one nonstomatal epidermal cells to follow the "one-cell-spacing" rule needed for efficient guard cell activity in gas exchange \[[@pgen.1008706.ref038], [@pgen.1008706.ref039]\]. To enforce this patterning rule, it was hypothesized that the developing guard cells release positional signals, e.g. the peptide ligand EPF1 \[[@pgen.1008706.ref040]\], that are perceived by the cell surface receptors, e.g. the receptor-like protein TMM \[[@pgen.1008706.ref020]\] and the receptor-like kinase ERL1 \[[@pgen.1008706.ref019], [@pgen.1008706.ref041]\] with the SERK co-receptors \[[@pgen.1008706.ref021]\], in the neighboring cells, so that the new divisions are reoriented to prevent direct stomatal contact from occurring \[[@pgen.1008706.ref042]\]. In addition, downstream of the ligand-receptor signaling, defective YDA MAPK activities also led to the failures in enforcing the one-cell-spacing rule \[[@pgen.1008706.ref005], [@pgen.1008706.ref006]\]. Therefore, it is possible that the elevated expression levels of MASS at the plasma membrane may directly or indirectly alleviate the ligand-receptor signaling and/or the YDA MAPK cascade activities in the regulation of division reorientation. An expanded survey for the MASS proteins to physically interact with the individual ER and SERK family members is necessary to test this connection.

The *MASS* genes, plant-specific and deeply conserved in early land plants {#sec011}
--------------------------------------------------------------------------

Through our sequence comparison and domain analysis, two conserved domains were recognized in the MASS protein family, including one segment at the N-terminus determining localization at the plasma membrane and another one at the C-terminus, containing the K/R-rich motif required for function and the putative MAPK phosphorylation motif P-P-S-P ([S4C Fig](#pgen.1008706.s004){ref-type="supplementary-material"}). We aligned three MASS proteins with 40 orthologs that can be identified in land plants (embryophytes) to generate the phylogenic tree ([S9 Fig](#pgen.1008706.s009){ref-type="supplementary-material"}). In the fern *Selaginella moellendorffii*, liverworts *Marchantia polymorpha*, as well as conifer *Picea sitchensis*, only one MASS-like (MASS-L) protein with the conserved N-terminal domain can be identified in their respective genome, suggesting their localization at the plasma membrane might be an ancient feature.

Interestingly, the typical MASS structure containing two conserved domains that appeared in the earliest flowering plant *Amborella trichopoda*, AmtMASS, and then the family members expand along with the evolution of angiosperms, e.g. 7 MASS genes in maize ([S9 Fig](#pgen.1008706.s009){ref-type="supplementary-material"}). In addition, based on the phylogenetic assay, we found that MASS3 is more similar to ancient AmtMASS. We suspect that the full-length MASS might be co-opted from an ancient form (MASS-L) with an additional C-terminal MAPK site and the functional domain to act as a MAPK substrate. Thus, these combined features of the MASS proteins enable them as MAPK-responding regulators for plants to adapt to the developmental and environmental changes.

Materials and methods {#sec012}
=====================

Plant materials, mutants and transgenic lines {#sec013}
---------------------------------------------

The *Arabidopsis thaliana* ecotyp*e* Columbia (Col-0) was used as the wild-type. In general, *Arabidopsis* and tobacco *Nicotiana benthamiana* plants were grown at 22°C in long days (16 h light/8 h dark). The T-DNA insertional lines *mass1* (GABI_902G09), *mass2* (SALK_061905), *mass3* (SALK_039099) were obtained from Arabidopsis Biological Resource Center (ABRC). The *GFP-BASL* marker line was described previously \[[@pgen.1008706.ref037]\].

Plasmid construction and plant transformation {#sec014}
---------------------------------------------

In general, the LR Clonase II (Invitrogen)-based gateway cloning technology was used for vector construction. To generate point mutations, the plasmid pENTR/D-TOPO carrying the *MASS* genomic or coding regions were used as template and specific site mutations were introduced through a QuickChange II XL Site-Directed Mutagenesis Kit (Agilent). The entry clones were then recombined into pMDC43 (the original *35S* promoter was replaced by *BASL* promoter) and pH35CG to make *BASLp*::GFP/YFP/mCherry-MASS and *35S*::CFP-MASS, respectively. Then, the *BASL* promoter were replaced by the *MASS* promoter through *PmeI* and *KpnI* sites to generate *MASS1p*::YFP-MASS1 and *MASS2p*::GFP-MASS2g. The pENTR/D-TOPO carrying *MASS* promoters were recombined into pBGYN to make *MASSp*::nucYFP.

To create CRISPR/Cas9-mediated mutagenesis in Arabidopsis, we adopted the system described in \[[@pgen.1008706.ref029]\]. By following the instructions, the oligos MASS1-CRI-F and MASS1-CRI-R were phosphorylated by T4 PNK (NEB) and annealed in a thermocycler, followed by ligation into the *BbsI* site of pAtU6-sgRNA-pAtUBQ-Cas9. Then, the chimeric U6-MASS1-Cas9 cassette was cloned into pCambia 2300 through *HindIII* and *EcoRI* sites to obtain 2300/crispr_mass1. U6-MASS3 was amplified by PCR and inserted into 2300/crispr_mass1 through *KpnI* and *EcoRI* sites to generate 2300/crispr_mass1;3. Finally, by using the same strategies, U6-MASS2 were inserted at *EcoRI* site to create the construct 2300/crispr_mass1;3;2 to knock-out the three members in the family. The *crispr* resistant MASS2 version (rMASS2) was generated through two rounds of PCR to introduce synonymous mutations in the Cas9-gRNA targeting site. Primers were listed in [S1 Table](#pgen.1008706.s010){ref-type="supplementary-material"}.

Plasmids were transformed into *Agrobacterium tumefaciens* GV3101, which delivers the desired DNA pieces into Arabidopsis or tobacco cells. *Arabidopsis* plants were transformed with the standard floral dipping method \[[@pgen.1008706.ref043], [@pgen.1008706.ref044]\] and transgenic seeds were subjected to antibiotic selection. Tobacco cells were infiltrated by the method described in \[[@pgen.1008706.ref045]\]. *A*. *tumefaciens* cells harboring *35S*::*CFP-MASS1/2/3* were infiltrated into *N*. *benthamiana* leaves and after 3 days, the leaf epidermal cells were observed under confocal microscope Leica SP5.

Plant cell imaging and image processing {#sec015}
---------------------------------------

Confocal images of plant cells expressing fluorescence-tagged proteins were taken by a Leica SP5 confocal microscope. 3-dpg (day-post-germination) adaxial cotyledons of Arabidopsis were captured. Cell peripheries were visualized with propidium iodide (PI, Invitrogen). Fluorescent proteins were excited at 488 nm (GFP), 514 nm (YFP) and 594nm (PI). Emissions were collected at 500--528 nm (GFP), 520-540nm (YFP), and 620--640 nm (PI). The confocal images were adjusted using either Adobe Photoshop CS5.1 or ImageJ (Fiji). The fluorescence intensity was measured by ImageJ (Fiji) and the pixel values were export into Excel to generate the histogram graphs.

Quantitative and statistical analysis of stomatal phenotypes in Arabidopsis {#sec016}
---------------------------------------------------------------------------

The adaxial cotyledons from 5-dpg seedlings were stained with PI and imaged were captured using a Carl Zeiss Axio Scope A1 fluorescence microscope equipped with a ProgRes MF CCD camera (Jenoptik). Stomata index (SI) was calculated as the stomata number versus the total number of epidermal cells. Clustered stomata index was calculated as the percentage of the number of clustered stomata over the total number of stomata. Stomatal clusters in [Fig 1C](#pgen.1008706.g001){ref-type="fig"} were counted on the adaxial surface of the 10-dpg cotyledons.

Real-time PCR {#sec017}
-------------

Total RNAs were extracted from 3-dpg seedlings using an RNeasy Plant Mini Kit (Qiagen). The first-strand cDNAs were synthesized by the SuperScrip First-Strand Synthesis System (Invitrogen) with 2μg of total RNAs as template in a total volume of 20 μl. The fragments of interest were amplified by sequence-specific primers (see [S1 Table](#pgen.1008706.s010){ref-type="supplementary-material"}). Real-time PCR was performed with a SYBR Green Master Mix kit (Applied Biosystems) and amplification was monitored on a StepOnePlus Real-Time PCR System (Applied Biosystems). Gene expression levels were normalized to the reference gene (*ACTIN2)* expression using the ΔCT method. Data are presented as mean ± SD.

Protein--protein interaction assay in yeast {#sec018}
-------------------------------------------

The yeast two-hybrid assay was performed using the Matchmaker GAL4 Two-Hybrid System according to the manufacturer's manual (Clontech). MASS2 was inserted into pGADT7 and YDA was inserted into pGBKT7, respectively. Plasmids were transferred into the yeast strain AH109 (Clontech) by the LiCl-PEG method. The interactions were tested on SD/-Leu/-Trp/-His plates supplemented with 5 mM 3-amino-1,2,4,-triazole (3-AT). Three independent clones for each transformation were tested.

Pull-down assay {#sec019}
---------------

The CDS fragments of MASS2 and YDA were cloned into pET28a or pMAL-c2x for *E*.*coli* expression of His- or MBP-tagged proteins, respectively. Constructs were introduced into BL21 (DE3) cells for recombinant proteins expression. The recombinant His-tagged MASS2 and MBP-tagged YDA were purified using Ni-NTA agarose (QIAGEN) or Amylose Resin (New England Biolabs), respectively, according to the manufacturer's protocol. For pull-down assays, 3 mg of MBP-YDA fusion protein was incubated with Amylose Resin at 4°C for 2 h, the MBP tag was used as a negative control. The beads were cleaned with washing buffer (50 mM Tris-HCl, pH 7.5, 10 mM MgCl2, 150 mM NaCl, and 1 mM DTT) for five times. Then the beads were incubated with 5 mg of His-MASS2 at 4°C for 2 h. Wash beads five times with washing buffer. Western blot was used to detect the SDS-PAGE separation results of pulled-down mixtures in nitrocellulose membrane with anti-His antibody (Cell Signaling Technology) and anti-MBP antibody (New England Biolabs).

Co-immunoprecipitation of interacting proteins in plants {#sec020}
--------------------------------------------------------

*Agrobacterium tumefaciens* strains (GV3101) carrying the 35S::4xMyc-MASS2g and the 35S::YDA^KI^-YFP plasmids were co-infiltrated into *N*. *benthamiana* leaves. YFP fluorescence was detected 72 h after co-infiltration, and leaves were harvested and ground to powder in liquid nitrogen. Total proteins were extracted with extraction buffer (50 mM Tris pH 7.5, 150 mM NaCl, 10% Glycerol, 1 mM EDTA, 1 mM EGTA, 1 mM NaF, 1 mM Na3VO4, 10 mM DTT, 1 mM β-glycerol phosphate, 1 mM PMSF, 1 tablet/10 ml of Protease Inhibitor cocktail (Roche)). Samples were centrifuged at 14,000 rpm for 30 at 4°C. Supernatant was subjected to immunoprecipitation by incubating with GFP-Trap Agarose (Chromotek) and rotating for 3 hr at 4°C. The beads were washed four times with extraction buffer and the immunoprecipitates eluted with 5x Loading buffer by boiling 10 min. Total protein extracts (input) and immunoprecipitated proteins were separated on 10% SDS-PAGE and transferred to polyvinylidene difluoride (PVDF) membranes. Samples were subjected to western blot analysis with anti-Myc (1:1000; Cell Signaling Technology) or anti-GFP (1:1000; Santa Cruz Biotechnology) antibody.

Bio-Layer interferometry (BLI) assay {#sec021}
------------------------------------

The binding affinity of MASS2 with YDA was measured using the BLItz system (ForteBio Inc.), as previously reported \[[@pgen.1008706.ref046]\]. The recombinant protein was purified and loaded onto Ni-NTA biosensors (ForteBio Inc.). Ni-NTA biosensors were first equilibrated in 50 mM Tris pH 8.0, 150 mM NaCl buffer for 10 min prior the measurements, then dipped in the buffer with purified YDA protein for the measurement of association and dissociation kinetics. The settings were as follows: initial base line for 30 s, loading for 120 s, base line for 30 s, association for 300 s, and dissociation for 500 s. The kinetic parameters Ka (association rate constant), Kd (dissociation rate constant) and the binding affinity (KD = Kd/Ka) were calculated with the help of data analysis software (BLItZ Pro). All the experiments were performed at room temperature.

Gene accession numbers in the study are *MASS1* (At1g80180), *MASS2* (At1g15400), *MASS3* (At5g20100), *YDA* (AT1G63700).

Supporting information {#sec022}
======================

###### MASS overexpression phenotype and expression pattern.

\(A\) Stomatal phenotype of MASS overexpression lines. Confocal images of 7-dpg adaxial side of the cotyledon epidermis in WT (Col) and CFP-MASS1, CFP-MASS2g, and CFP-MASS3 seedlings, all driven by *35S* promoter. Brackets indicate stomatal clusters. Scale bars represent 50 μm. (B) Confocal images to show transcriptional activities of the *MASS1/2/3* promoters displayed by the expression of nuclear YFP (nucYFP, green). Cell outlines were stained with Propidium Iodide (PI). The inset showing more detailed expression pattern. Scale bar represents 50 μm in (A) and 20 μm in (B).

(TIF)

###### 

Click here for additional data file.

###### Genetic characterization of the *mass* mutants.

\(A\) Diagram of the gene structure and splicing variants of the *MASS* genes. (B) Genotyping results for the *crispr* mutants. DNA sequence alignments showing the edited DNA sequences of the three *MASS* gene editing in *mass1;2;3-crispr* \#5 and \#7 lines. The PAM sequences were outlined with blue boxes, sgRNAs were underlined with red. (C) Genotyping PCR showing a long deletion in *MASS1* in a T3 *mass1;2;3-crispr* \#7 mutant plant. (D) Quantification of SI in 5-dpg adaxial cotyledons of *mass1;2;3-crispr \#5* and *\#7* mutant. \*\* significantly different between the two samples being compared (bars). Student's *t*-test, \*\*P \< 0.001.

(TIF)

###### 

Click here for additional data file.

###### MASS1 functions at plasma membrane in stomatal lineages.

\(A\) *MASS1pro*::YFP-MASS1 (B) *MASS2pro*::GFP-MASS2 in T-DNA triple mutants at 3-dpg. Note, strong signals of YFP-MASS1 in the mesophyll cell layer (A), whilst strong YFP-MASS2 in the epidermis (B). (C, D) Confocal images showing stomatal phenotype in plasma membrane-localized (C) and nuclear-localized (D) GFP-MASS1 seedlings, both driven by the *BASL* promoter. Green: GFP signals, magenta: cell outlines stained with PI. Left panels show protein localization, right panels show the overlay of green and magenta. White brackets indicate stomatal clusters and abnormal cell divisions. Scale bar represents 50 μm.

(TIF)

###### 

Click here for additional data file.

###### Subdomain analysis of MASS proteins.

\(A\) Amino acid alignment of the MASS2 splicing variants. (B) Confocal images showing the detailed localization of GFP-tagged MASS2g, MASS2.1, MASS2.2, and MASS2.3 (green), all driven by the *BASL* promoter. Scale bar represents 10 μm. (C) Amino acid alignment of MASS1, MASS2.3, and MASS3 and the identified subdomains required for specific functions. The deleted amino acids to make GFP-MASS2.3 truncations were outlined with designated colors. (D) Confocal images of 3-dpg adaxial side of the cotyledon epidermis showing localization and stomatal phenotype of truncated MASS2.3 proteins. Cell outlines were stained with PI. Scale bar represents 20 μm.

(TIF)

###### 

Click here for additional data file.

###### Subcellular localization of MASS phospho-variants.

\(A\) Confocal images of YFP-MASS1 and phospho-variants shown as single optical section (s) *vs*. the z-projections (z). (B) Confocal images of YFP-MASS2.2 and phospho-variants in single optical section (s). Scale bar represents 50 μm.

(TIF)

###### 

Click here for additional data file.

###### Subcellular localization of MASS in MPK3/6-deficient background.

\(A\) Confocal images to show *35S*::CFP-MASS2g (red) co-expression with overexpression of the dominant negative (kinase inactive) MPK6 (*BASLp*::MPK6AEF-mRFP, green). Scale bar represents 20 μm. (B) Confocal images of *BASLp*::mCherry-MASS2 (red) co-expressed with *35S*::MPK6AEF-YFP (green). Scale bar represents 50 μm. (C) Confocal images of GFP-MASS in chemically inducible MPK6 inhibition in *mpk3;6* null background. Scale bar represents 50 μm. (D) 5-day-old seedlings of WT, *mass1;2;3* and YDA^CA^.

(TIF)

###### 

Click here for additional data file.

###### Interaction between YDA and MASS.

\(A\) Confocal images to show BiFC interaction tests between YDA^KI^ and MASS1/3 in tobacco leaf epidermis. The expression of half YFP (cYFP) was used as negative control. Scale bar represents 50 μm. (B) BLI tests to show the interaction between YDA and MASS2. The BASL-YDA interaction was used as positive control, while MPK6-YDA as negative control. (C) Western blot to test activated MPK3/6 levels in *mass* mutants and overexpression plants. (D) *In vitro* YDA^CA^ autophosporylation levels by *in vitro* kinase assay. Increasing amount of MASS2 was added to test whether it affects YDA^CA^ autophosporylation activity. MKK5^KI^ as a positive control, in which elevated levels of YDA^CA^ trigger elevated phosphorylation of MKK5.

(TIF)

###### 

Click here for additional data file.

###### Genetic relationship between MASS proteins and other stomatal regulators.

\(A\) Genetic test between *er105* and a GFP-MASS2g overexpression line, driven by *BASL* promoter. Cell outlines were stained with PI (red). (B) Confocal images showing localization of Venus-BASL (green) and mCherry-MASS2g (red), both driven by the *BASL* promoter. Scale bar represents 50 μm.

(TIF)

###### 

Click here for additional data file.

###### Phylogenetic tree of the MASS family.

Protein sequences of the three Arabidopsis MASS proteins were compared with those of 40 orthologs retrieved by GenBank blasting representing embryophyta (lycophyte, gymnosperm and angiosperms). Phylogenetic tree was constructed by the program MEGA6 \[[@pgen.1008706.ref047]\] using the neighbor-joining method. The reliability of the phylogenetic tree was evaluated by bootstrapping of 1000 replications.

(TIF)

###### 

Click here for additional data file.

###### Primers used in this study.

(PDF)

###### 

Click here for additional data file.

###### Raw data for quantification.

(XLSX)

###### 

Click here for additional data file.
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Dear Dr Dong,

Thank you very much for submitting your Research Article entitled \'The MAPK substrate MASS proteins regulate stomatal development in Arabidopsis\' to PLOS Genetics. Your manuscript was fully evaluated at the editorial level and by independent peer reviewers. The reviewers appreciated the attention to an important problem, but raised some substantial concerns about the current manuscript. Based on the reviews, we will not be able to accept this version of the manuscript, but we would be willing to review again a much-revised version. We cannot, of course, promise publication at that time.

There are a few major issues that need to be addressed in the next version of the manuscript. First, please discuss your findings in the context of previously published literatures (e.g. Sorensson et al., Biochem J., 2012). Second, as YDA-MASS interaction is a key conclusion in this manuscript, we highly recommend that you perform Co-IP experiments to test their interaction in Arabidopsis. Third, analysis of MASS proteins driven by their own promoters is highly recommended in some key experiments. Fourth, some Z-projection data should be included in confocal analysis particularly in the cases where you exclude protein localization in some organelles. In addition, it is important to understand the effects of the YDA-MASS interaction pertaining to the questions like whether this interaction affects subcellular localization of YDA or MASS proteins, and how this interaction suppresses the inhibitory function of YDA in stomatal development.

Should you decide to revise the manuscript for further consideration here, your revisions should address the specific points made by each reviewer. We will also require a detailed list of your responses to the review comments and a description of the changes you have made in the manuscript.

If you decide to revise the manuscript for further consideration at PLOS Genetics, please aim to resubmit within the next 90 days, unless it will take extra time to address the concerns of the reviewers, in which case we would appreciate an expected resubmission date by email to <plosgenetics@plos.org>.

If present, accompanying reviewer attachments are included with this email; please notify the journal office if any appear to be missing. They will also be available for download from the link below. You can use this link to log into the system when you are ready to submit a revised version, having first consulted our [Submission Checklist](http://journals.plos.org/plosgenetics/s/submit-now#loc-submission-checklist).

To enhance the reproducibility of your results, we recommend that you deposit your laboratory protocols in protocols.io, where a protocol can be assigned its own identifier (DOI) such that it can be cited independently in the future. For instructions see our [guidelines](http://journals.plos.org/plosgenetics/s/submission-guidelines#loc-materials-and-methods).

Please be aware that our [data availability policy](http://journals.plos.org/plosgenetics/s/data-availability) requires that all numerical data underlying graphs or summary statistics are included with the submission, and you will need to provide this upon resubmission if not already present. In addition, we do not permit the inclusion of phrases such as \"data not shown\" or \"unpublished results\" in manuscripts. All points should be backed up by data provided with the submission.

While revising your submission, please upload your figure files to the [Preflight Analysis and Conversion Engine](http://pace.apexcovantage.com/) (PACE) digital diagnostic tool.  PACE helps ensure that figures meet PLOS requirements. To use PACE, you must first register as a user. Then, login and navigate to the UPLOAD tab, where you will find detailed instructions on how to use the tool. If you encounter any issues or have any questions when using PACE, please email us at <figures@plos.org>.

PLOS has incorporated [Similarity Check](http://www.crossref.org/crosscheck.html), powered by iThenticate, into its journal-wide submission system in order to screen submitted content for originality before publication. Each PLOS journal undertakes screening on a proportion of submitted articles. You will be contacted if needed following the screening process.

To resubmit, use the link below and \'Revise Submission\' in the \'Submissions Needing Revision\' folder.

\[LINK\]

We are sorry that we cannot be more positive about your manuscript at this stage. Please do not hesitate to contact us if you have any concerns or questions.

Yours sincerely,

Hao Yu

Associate Editor

PLOS Genetics

Gregory P. Copenhaver

Editor-in-Chief

PLOS Genetics

Reviewer\'s Responses to Questions

**Comments to the Authors:**

**Please note here if the review is uploaded as an attachment.**

Reviewer \#1: Xue et al. reports a family of MAP Kinase substrate proteins, MASS proteins, that positively regulate stomatal development. The most striking finding is plasma membrane (PM) -nucleus localization dynamics of MASS and the demonstration that PM-localized MASS confers functions. All of these remind of the subcellular dynamics and MAPK regulation of BASL, which have been extensively studied by the authors' group, although the regulatory relationship between MASS proteins and BASL are not addressed in this manuscript.

The microscopy images presented are very beautiful, and the manuscript adds very interesting family of proteins to plant specific cellular polarity modules. Having said that, there are several critical issues that need to be addressed in order to improve the manuscript.

1\) Sorensson et al. report: First of all, the authors should properly acknowledge the previous work done by Sorensson et al. (Biochem J. 2012), who reported the identification of At1g80180 MASS protein (and its related protein At1g15400, now named MASS2) as in vitro and in planta MPK3/6 substrates that positively regulates stomatal development. Sorensson et al. have done quite in-depth experiments beyond this Xue et al. manuscript mentions. For example, Sorensson et al. have identified the MPK3/6 phosphosites of MASS1, performed site-directed mutagenesis to show site S105 is the phosphosite; the in vivo phosphorylation of MASS2 was reported by Scott Peck's group; 2004 Plant Cell, which makes Xue's phosphorylation experiments (Fig. 5A) rather confirmatory.

More importantly, Sorensson et al. performed overexpression study of MASS protein, and reported that overexpressed phosphomimic version (S105D) confers stomatal clustering and increased stomatal index in Arabidopsis. This further diminishes Xie et al.'s Result section (line 122- 1st paragraph; Figure 1), making it largely confirmatory, and the authors' statement "we noted that one striking phenotype caused by MASS overexpression was clustered stomata" (lines 407-408) highly misleading, as it has been reported previously.

Third, Sorensson et al. has reported the uniform promoter activity of MASS in developing cotyledons using MASSpro::GUS construct. The MASSpro::nucYFP expression analysis (Fig. S1) does not provide much more insight\-\-- What new here is that Xue et al. also characterized the promoter activity of MASS2 and MASS3.

Thus, the major conclusion of MASS proteins as positive regulator of stomatal development and MPK3/6 substrates have been reported. Here, Xue et al. have done more careful analysis using sophisticated confocal microscopy and beautiful images---however, the manuscript needs to be re-written and re-organized to properly and fairly acknowledge the previous findings.

2\) Lack of analysis using endogenously expressed MASS proteins: Here all experiments of subcellular localization and interaction studies are done using ectopic promoters in the stomatal cell lineage promoters (e.g. 35S promoter, BASL promoter, SPCH promoter---Data presented in Figs. 1,3, 4,5,6,7). While use of ectopic promoters will provide "cleaner" results to interpret data-thus could be a powerful tool, however, caution should be made as it is after all ectopic expression.

I don't see any YFP signal in Fig. 2C when the endogenous promoter was used (MASS1/2/3pro::YFP-MASS1/2/3). Is the endogenous expression that low?

Do the BASLpro:MASS1/2/3 complement the modest low stomatal index phenotype of mass1/2/3? Or does it still constitutively-active and causes excessive stomatal lineage divisions? If the latter, I would be very cautious in interpreting the subcellular localization.

Based on Fig. S1B, the promoter activity of MASS1-3 are much higher in pavement cells (and they are not expressed in stomatal precursor cells and stomatal guard cells). Where do MASS proteins localize in the pavement cells?

3\) YDA-MASS interactions: The novelty (and exciting findings) of this manuscript lies in subcellular localization dynamics and precise mapping of MASS in YDA-MAPK cascade. The YDA-MASS association are tested in in vitro pull down, BiFC and Y2H (Fig. 6A-C), all highly sensitive yet occasionally face false positives, and lacking in vivo subcellular contexts. The co-localiation of YDA and MASS in plasma membrane speckle is interesting, however, again, ectopic promoters (SPCH promoter and BASL promoter) are used for expressing MASS and YDA. Overexpression of fluorescent tagged proteins are known to often form aggregates, and I think it is important for the authors to perform Co-IP experiments of YDA-MASS interactions using endogenously expressed (i.e. epitope-tagged proteins driven by the endogenous promoter) YDA and MASS.

3\) Genetic interactions of MASS with YDA-MAPK cascade: Again, the genetic studies are done with ectopic expression of MASS vs ectopic expression of YDA (Fig. 7), which could be misleading. The authors need to present genetic analysis using loss-of-function mutants, which properly places the components in the genetic pathway. Because the phenotype of mass1/2/3 triple loss-of-function mutants is so subtle/weak, it may be masked by strong yda loss-of-function phenotype. However, the authors could test mass1/2/3 interactions with mpk3 and mpk6. Since mpk3 and mpk6 single mutants have no stomatal phenotype (or slightly elevated stomatal index, as reported by Putarjunan et al. 2019), the mass1/2/3 could counteract with the modest elevated stomatal index phenotype of mpk3 and mpk6.

4\) Subcellular localization of MASS proteins in YDA-MAPK mutants: The authors mention that neigher phosphomimic or phosphonull substitutions of MASS proteins properly localize to PM (Fig. 5; lines 266-268). What are the subcellular localizations of YFP-MASS1/2/3 in mpk3/6 double and YDA mutants? This need to be characterized to confirm that YDA-MPK3/6 are indeed required for proper PM localization of MASS.

5\) Positive role of MAPK: In the Intro (and at some extent in Discussion), the authors rationalize their study mentioning that MAPK pathway components that positively regulate stomatal development is not well studied (lines 77-79). The Lampard et al. 2009 and 2014 Plant Cell papers show that the YDA-MKK7/9-MPK3/6 module promotes stomatal development when expressed in the later stomatal precursor cells (GMC-to young guard cells, driven by the FAMA promoter). None of the expression studies of Xue et al. manuscript are done in the later stage of stomatal precursors. As far as I can see from Fig. S1, the MASS1/2/3 promoters are not even active in the GMC-young GCs. How could the authors imply the role of MASS proteins in the known positive pathway?

6\) Intro-ICE1: Recent study identifies ICE1 as a scaffold to recruit MPK3/6 to nucleus, to bridge to SPCH, which does not physically associate with MPK3/6 (Putarjunan et al., 2019). Thus, the Introduction mentioning that "ICE1 is also phosphorylated by MPK3/6 (line 86-)" (and also related sentence in Discussion) is not properly reflecting the current knowledge.

Minor: Fig. 5A "CCB" should be "CBB"?

Reviewer \#2: The authors present a considerable body of work examining the role of MASS proteins in stomatal development. Along with mutant and overexpressors, the study examines localization and motif analysis as well as protein-interaction studies. The study concludes that the MASS proteins represent novel positive regulators of stomatal development that act in a localization dependent manner to inhibit the activity of the MAPKKK YDA. Overall, this body of work presents novel insight into the MAPK module that regulates stomatal development and is clearly present and discussed. There are however, components of the study that require clarification or expansion to fully justify the author's conclusions.

Minor comments

SI graphs would be better presented as violin plots or box and whiskers to show the distribution of the data.

qRT-PCR expression analysis graphs should also show the data points. Both of these are relatively common requests with regards presentation.

P8 Line 145 '....mutant produced lowered density of stomatal guard cells.' Here the authors are referring to SI data and so this should reflect that this is a proportion and not density.

Figure 2C/F. The authors refer to the complementation lines in the insertion mutant but the SI data for these lines is missing from 2F.

The various fusion proteins and the resulting microscopy is given as proof of localization. For clarity, it would be good to see some blots probed with a GFP-antibody to demonstrate that these are fusions and that there is not significant free-GFP contributing to the signal.

P15 line 295. Can you really not show the data here -- if it resembles the CA-YDA then it would be good to see.

Major comments

Confocal imaging is vital here for demonstrating the localization but there is little detail in the methods regarding the image capture and post-capture processing. To demonstrate fully the different localisations seen, some Z-projections are required in supplemental data. This is particular the case when the argument is that the protein is only at the membrane or the nucleus -- a single plane is not sufficient to demonstrate this.

Interactions with YDA. Personally, for in planta interaction, a Co-Ip would be stronger proof than the in vitro method (not in planta), BiFC or the co-localisation. Certainly, these two latter results could potentially be explained by interactions with MPK6 and this being in close proximity to YDA.

The authors utilize the correct methodology to examine the role of phosphorylation (generating phosphomimics and mutants). However, the results are confusing. I'd like to add that the authors have been clear in reporting this and it's good to see these results reported. However, I think that the resulting interpretation is only one possible explanation. If the argument is that phosphorylation is important for targeting then yes, you would hope to see differential localization. The alternative explanation is that the amino acid changes have both altered function independent of any role of phosphorylation. What would perhaps be useful in resolving this would be an analysis of the CFP-MASS2 localisation when crossed with the constitutively active version of YDA (7a). Here, you would at least expect enhanced MPK6 activity and MASS phosphorylation -- so do you see an overall change in membrane versus nuclear localization?

On a similar front. If the expectation is that these MASS proteins inhibit YDA and therefore activation of the MAPK pathway, you might expect to see higher basal MPK6 activity in the mass triple mutant and lower MPK6 activity in the OE lines -- this can be tested with phosphor specific antibodies. This could also be correlated with gene expression analysis of SPCH and some of its targets.

In their discussion, the differential localization of BASL is discussed and the similarities drawn with the localization of the MASS proteins. Linking to above, a question that arises is therefore, where is MPK6 phosophorylation these MASS proteins? In the nucleus or is it the cytoplasm or when they associate with the PM? The author's discussion suggest they favour a nuclear phosphorylation event. I'm not suggesting that they determine this though I believe that they have the tools to do so. However, they could therefore slightly expand their discussion here to discuss the relevance to signalling of this model -- they suggest it is a pool for responding to signals but the implications are that this would be a potential feedback mechanism to bring the MAPK signal back to normal. The question would then be what the stability is of the MASS proteins at the PM and whether they are dephosphorylated and then re-targetted or just broken down. Basically, their model could be expanded on.

Reviewer \#3: In their manuscript, Xue et al., identified a novel family of small proteins that are involved in stomatal development. A member of this 3-protein family named MASS was previously found to be a substrate of MPK3/6. Through overexpression and mutant analyses, the authors first demonstrated that the MASS proteins act to promote stomatal production. Fluorescent reporters showed that the MASS proteins are localized either to both the plasma membrane and the nucleus or exclusively to the plasma membrane, and that they exert their function on the plasma membrane. Deletion and amino acid substitution analyses further identified that specific protein domains and the MPK6-targeted phosphorylation site on MASS2 are important for its subcellular localization and function. Finally, the authors found that MASS proteins physically interact with the triple MAP kinase YDA and appear to suppress the inhibitory function of YDA in stomatal development.

The YDA-mediated MAP kinase pathway is a key module in regulating stomatal development and patterning, as well as in other developmental processes. Thus, it is of great interest to understand how YDA is regulated. The identification of the MASS proteins as new stomatal regulators acting through YDA provides novel insights into the regulation of this critical signalling pathway. The functional dissection of the domains and the phosphorylation site also yielded valuable information about these proteins. In addition, the quality of data and the writing are generally good. To further strengthen manuscript, here are a few points that I would like the authors to address:

1\. The authors mentioned that the overexpression of MASS proteins produced "overproliferated early stomatal lineage... cells" (Line 131) but did not show any quantitative data. Since these "early lineage cells" are highly relevant to YDA activity, I think the authors should quantify them in young cotyledons/leaves in the overexpression and the triple mutants.

2\. The stomatal index data for mass1;2;3-crispr\#5 and rescued lines were mentioned but are missing (Line 164 and Line 172).

3\. For the BiFC (Fig. 6C and S5A), there should be another negative control with nYFP and YDA-KI-CFP.

4\. The kinase inactive YDA was previously shown to cause a dominant negative phenotype (i.e. over-proliferation of the stomatal lineage) (Lampard et al., 2009). If the authors have the relevant data, I think the authors could indicate whether the overexpression of MASS2g (Fig. 6D) can further enhance the dominant negative phenotype.

5\. Since the authors are the first to characterize this protein family, it would be helpful to the community to indicate if the mutants have other obvious growth defects and if these proteins are expressed in other tissues or developmental stage.

Others:

\- The AGI code for MASS3 in the text (Line128) and the figure is not correct (compared with Line 452)

\- In Fig. 6B, the authors should indicate more clearly in the figure or legend that MBP and MBP-YDA were used as baits.

\*\*\*\*\*\*\*\*\*\*

**Have all data underlying the figures and results presented in the manuscript been provided?**

Large-scale datasets should be made available via a public repository as described in the *PLOS Genetics* [data availability policy](http://journals.plos.org/plosgenetics/s/data-availability), and numerical data that underlies graphs or summary statistics should be provided in spreadsheet form as supporting information.

Reviewer \#1: Yes

Reviewer \#2: No: The complementation data appears to have been left out of one graph and they do say data not shown elsewhere for a phenotype.

Reviewer \#3: None

\*\*\*\*\*\*\*\*\*\*

PLOS authors have the option to publish the peer review history of their article ([what does this mean?](https://journals.plos.org/plosgenetics/s/editorial-and-peer-review-process#loc-peer-review-history)). If published, this will include your full peer review and any attached files.

If you choose "no", your identity will remain anonymous but your review may still be made public.

**Do you want your identity to be public for this peer review?** For information about this choice, including consent withdrawal, please see our [Privacy Policy](https://www.plos.org/privacy-policy).

Reviewer \#1: No

Reviewer \#2: No

Reviewer \#3: No
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\* Please note while forming your response, if your article is accepted, you may have the opportunity to make the peer review history publicly available. The record will include editor decision letters (with reviews) and your responses to reviewer comments. If eligible, we will contact you to opt in or out. \*

Dear Dr Dong,

Thank you very much for submitting your Research Article entitled \'The MAPK substrate MASS proteins regulate stomatal development in Arabidopsis\' to PLOS Genetics. Your manuscript was fully evaluated at the editorial level and by independent peer reviewers who reviewed the last version of this manuscript. The reviewers appreciated your revisions, but identified some aspects of the manuscript that should be further improved.

We therefore ask you to modify the manuscript according to the review recommendations before we can consider your manuscript for acceptance. Your revisions should address the specific points made by Reviewer 2. Based on the results presented in the manuscript, you may consider to tone down the conclusions in the MPK3/6 regulatory role in mediating MASS activity and localisation.

In addition we ask that you:

1\) Provide a detailed list of your responses to the review comments and a description of the changes you have made in the manuscript.

2\) Upload a Striking Image with a corresponding caption to accompany your manuscript if one is available (either a new image or an existing one from within your manuscript). If this image is judged to be suitable, it may be featured on our website. Images should ideally be high resolution, eye-catching, single panel square images. For examples, please browse our [archive](http://www.plosgenetics.org/article/browse/volume). If your image is from someone other than yourself, please ensure that the artist has read and agreed to the terms and conditions of the Creative Commons Attribution License. Note: we cannot publish copyrighted images.

We hope to receive your revised manuscript within the next 30 days. If you anticipate any delay in its return, we would ask you to let us know the expected resubmission date by email to <plosgenetics@plos.org>.

If present, accompanying reviewer attachments should be included with this email; please notify the journal office if any appear to be missing. They will also be available for download from the link below. You can use this link to log into the system when you are ready to submit a revised version, having first consulted our [Submission Checklist](http://journals.plos.org/plosgenetics/s/submit-now#loc-submission-checklist).

While revising your submission, please upload your figure files to the [Preflight Analysis and Conversion Engine](http://pace.apexcovantage.com/) (PACE) digital diagnostic tool. PACE helps ensure that figures meet PLOS requirements. To use PACE, you must first register as a user. Then, login and navigate to the UPLOAD tab, where you will find detailed instructions on how to use the tool. If you encounter any issues or have any questions when using PACE, please email us at <figures@plos.org>.

Please be aware that our [data availability policy](http://journals.plos.org/plosgenetics/s/data-availability) requires that all numerical data underlying graphs or summary statistics are included with the submission, and you will need to provide this upon resubmission if not already present. In addition, we do not permit the inclusion of phrases such as \"data not shown\" or \"unpublished results\" in manuscripts. All points should be backed up by data provided with the submission.

PLOS has incorporated [Similarity Check](http://www.crossref.org/crosscheck.html), powered by iThenticate, into its journal-wide submission system in order to screen submitted content for originality before publication. Each PLOS journal undertakes screening on a proportion of submitted articles. You will be contacted if needed following the screening process.

To resubmit, you will need to go to the link below and \'Revise Submission\' in the \'Submissions Needing Revision\' folder.

\[LINK\]

Please let us know if you have any questions while making these revisions.

Yours sincerely,

Hao Yu

Associate Editor

PLOS Genetics

Gregory P. Copenhaver

Editor-in-Chief

PLOS Genetics

Reviewer\'s Responses to Questions

**Comments to the Authors:**

**Please note here if the review is uploaded as an attachment.**

Reviewer \#2: The authors have provided a much improved manuscript with new data to address the concerns raised by this reviewer.

There are two major aspects to consider here. Firstly, the MPK3/6 aspect and secondly the YDA aspect. With regards YDA, the authors provide new and strong data to support their conclusion that the MASS proteins interact with YDA. Whilst it is not clear how this impacts on YDA activity based on the authors experiments (S7D), the genetics (Fig 7B) and the phospho-kinase blot (S7c) suggest that YDA-MKK-MPK activity is impacted. With regards S7C, it is customary to strip and reprobe with the anti-MPK6 antibody to show loading rather than show gel loading.

Where there is less clarity is the role of MPK3/6 phosphorylation. The authors maintain that MPK3/6 mediated phosphorylation of Ser 107 is impacting localisation and function however, the data is still inconclusive. Certainly, mutation of this residue interferes with PM-nuclear partitioning and activity but this is not the same as concluding that MPK3/6 phosphorylation of this residue regulates these two factors. This remains the main issue with the conclusions - the data is not conclusive in showing that MPK3/6 has this regulatory role and I think the authors should tone down these conclusions. I should add that the authors have been open in there analysis and reporting of results however, given this, I don\'t think this role for MPK3/6 is conclusive.

Reviewer \#3: The authors have addressed all my concerns in their revision.

\*\*\*\*\*\*\*\*\*\*

**Have all data underlying the figures and results presented in the manuscript been provided?**

Large-scale datasets should be made available via a public repository as described in the *PLOS Genetics* [data availability policy](http://journals.plos.org/plosgenetics/s/data-availability), and numerical data that underlies graphs or summary statistics should be provided in spreadsheet form as supporting information.

Reviewer \#2: None

Reviewer \#3: Yes

\*\*\*\*\*\*\*\*\*\*

PLOS authors have the option to publish the peer review history of their article ([what does this mean?](https://journals.plos.org/plosgenetics/s/editorial-and-peer-review-process#loc-peer-review-history)). If published, this will include your full peer review and any attached files.

If you choose "no", your identity will remain anonymous but your review may still be made public.

**Do you want your identity to be public for this peer review?** For information about this choice, including consent withdrawal, please see our [Privacy Policy](https://www.plos.org/privacy-policy).

Reviewer \#2: No

Reviewer \#3: No

10.1371/journal.pgen.1008706.r004
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Dear Dr Dong,

We are pleased to inform you that your manuscript entitled \"The MAPK substrate MASS proteins regulate stomatal development in Arabidopsis\" has been editorially accepted for publication in PLOS Genetics. Congratulations!

Before your submission can be formally accepted and sent to production you will need to complete our formatting changes, which you will receive in a follow up email. Please be aware that it may take several days for you to receive this email; during this time no action is required by you. Please note: the accept date on your published article will reflect the date of this provisional accept, but your manuscript will not be scheduled for publication until the required changes have been made.

Once your paper is formally accepted, an uncorrected proof of your manuscript will be published online ahead of the final version, unless you've already opted out via the online submission form. If, for any reason, you do not want an earlier version of your manuscript published online or are unsure if you have already indicated as such, please let the journal staff know immediately at <plosgenetics@plos.org>.

In the meantime, please log into Editorial Manager at <https://www.editorialmanager.com/pgenetics/>, click the \"Update My Information\" link at the top of the page, and update your user information to ensure an efficient production and billing process. Note that PLOS requires an ORCID iD for all corresponding authors. Therefore, please ensure that you have an ORCID iD and that it is validated in Editorial Manager. To do this, go to 'Update my Information' (in the upper left-hand corner of the main menu), and click on the Fetch/Validate link next to the ORCID field.  This will take you to the ORCID site and allow you to create a new iD or authenticate a pre-existing iD in Editorial Manager.

If you have a press-related query, or would like to know about one way to make your underlying data available (as you will be aware, this is required for publication), please see the end of this email. If your institution or institutions have a press office, please notify them about your upcoming article at this point, to enable them to help maximise its impact. Inform journal staff as soon as possible if you are preparing a press release for your article and need a publication date.

Thank you again for supporting open-access publishing; we are looking forward to publishing your work in PLOS Genetics!

Yours sincerely,

Hao Yu

Associate Editor

PLOS Genetics

Gregory P. Copenhaver

Editor-in-Chief

PLOS Genetics

[www.plosgenetics.org](http://www.plosgenetics.org)

Twitter: \@PLOSGenetics
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Comments from the reviewers (if applicable):

\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\--

**Data Deposition**

If you have submitted a Research Article or Front Matter that has associated data that are not suitable for deposition in a subject-specific public repository (such as GenBank or ArrayExpress), one way to make that data available is to deposit it in the [Dryad Digital Repository](http://www.datadryad.org). As you may recall, we ask all authors to agree to make data available; this is one way to achieve that. A full list of recommended repositories can be found on our [website](http://journals.plos.org/plosgenetics/s/data-availability#loc-recommended-repositories).

The following link will take you to the Dryad record for your article, so you won\'t have to re‐enter its bibliographic information, and can upload your files directly: 

<http://datadryad.org/submit?journalID=pgenetics&manu=PGENETICS-D-19-01431R2>

More information about depositing data in Dryad is available at <http://www.datadryad.org/depositing>. If you experience any difficulties in submitting your data, please contact <help@datadryad.org> for support.

Additionally, please be aware that our [data availability policy](http://journals.plos.org/plosgenetics/s/data-availability) requires that all numerical data underlying display items are included with the submission, and you will need to provide this before we can formally accept your manuscript, if not already present.

\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\--

Press Queries

If you or your institution will be preparing press materials for this manuscript, or if you need to know your paper\'s publication date for media purposes, please inform the journal staff as soon as possible so that your submission can be scheduled accordingly. Your manuscript will remain under a strict press embargo until the publication date and time. This means an early version of your manuscript will not be published ahead of your final version. PLOS Genetics may also choose to issue a press release for your article. If there\'s anything the journal should know or you\'d like more information, please get in touch via <plosgenetics@plos.org>.
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PGENETICS-D-19-01431R2

The MAPK substrate MASS proteins regulate stomatal development in Arabidopsis

Dear Dr Dong,

We are pleased to inform you that your manuscript entitled \"The MAPK substrate MASS proteins regulate stomatal development in Arabidopsis\" has been formally accepted for publication in PLOS Genetics! Your manuscript is now with our production department and you will be notified of the publication date in due course.

The corresponding author will soon be receiving a typeset proof for review, to ensure errors have not been introduced during production. Please review the PDF proof of your manuscript carefully, as this is the last chance to correct any errors. Please note that major changes, or those which affect the scientific understanding of the work, will likely cause delays to the publication date of your manuscript.

Soon after your final files are uploaded, unless you have opted out or your manuscript is a front-matter piece, the early version of your manuscript will be published online. The date of the early version will be your article\'s publication date. The final article will be published to the same URL, and all versions of the paper will be accessible to readers.
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